FDA Acceptance of Lenalidomide Supplement Application by Mylan
The FDA has accepted Mylan's supplemental application for Lenalidomide under ANDA213912.
Published: July 6, 2026
Updated: July 6, 2026
Author: Humanexa Intelligence
Therapeutic area: Oncology / Small Molecule
Company: Mylan
Asset: Lenalidomide
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
Mylan
Asset
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's acceptance of Mylan's supplemental application for Lenalidomide is significant as it may strengthen Mylan's competitive position in the oncology market. This development necessitates close monitoring of pricing dynamics and market share implications for existing Lenalidomide alternatives.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the timeline for final approval and any potential market entry dates.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.